Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series

BACKGROUND: Neoadjuvant chemoimmunotherapy seems to be a promising treatment option for stage III non-small cell lung cancer (NSCLC). Sintilimab, as a programmed death receptor-1 inhibitor, has exhibited a fine performance in treating NSCLC. However, the efficiency of sintilimab combined with chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Bo-Shi, Wang, Xing-Tong, Di, Shou-Yin, Zhao, Jia-Hua, Chen, Si-Yu, Zhou, Shao-Hua, Yue, Cai-Ying, Song, Wei-An, Gong, Tai-Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273648/
https://www.ncbi.nlm.nih.gov/pubmed/35836545
http://dx.doi.org/10.21037/tcr-22-1194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273648/
https://www.ncbi.nlm.nih.gov/pubmed/35836545
http://dx.doi.org/10.21037/tcr-22-1194

Ejemplares similares